Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low‐dose aspirin and nonsteroidal anti‐inflammatory drugs
Authors:
Open Access
- 1 September 2008
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 28 (7) , 878-885
Abstract
Summary: Background It is not clear whether the incidence or early mortality related to peptic ulcer perforation has changed.Aim To evaluate the incidence and mortality related to peptic ulcer perforation while considering the intake of low‐dose aspirin and nonsteroidal anti‐inflammatory drugs (NSAIDs).Methods We recorded the numbers and details of all patients presenting in our region of Scotland with perforation between 1997 and 2006 including demography, drug usage and 30‐day mortality.Results In subjects aged >65 years, the annual incidence of perforation was 32.7 per 105 of the age‐specific population, of whom 10.7 per 105 were taking low‐dose aspirin and 12.0 taking NSAIDs. These were all significantly higher (P < 0.001) than the corresponding incidence in subjects aged ≤65 years (6.6 per 105 overall, 1.1 taking aspirin and 2.5 taking NSAIDs). There was an increasing trend with time in the number of patients taking NSAIDs (χ2 = 4.57, P = 0.03). Using univariate analysis, 30‐day mortality was associated with aspirin [odds ratio, 2.32 (95% C.I., 1.20–4.47), P = 0.01] but not with NSAIDs. The strongest predictors of mortality were increasing age and comorbidity.Conclusions Perforation remains common in elderly patients including users of NSAIDs and aspirin. Early mortality is also noted in association with increasing age and comorbidity, but not independently with drug intake.Keywords
This publication has 24 references indexed in Scilit:
- Overprescribing proton pump inhibitorsBMJ, 2008
- Upper gastrointestinal bleeding and the changing use of COX‐2 non‐steroidal anti‐inflammatory drugs and low‐dose aspirinAlimentary Pharmacology & Therapeutics, 2007
- Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcerAlimentary Pharmacology & Therapeutics, 2007
- Review article: gastrointestinal bleeding with low‐dose aspirin – what's the risk?Alimentary Pharmacology & Therapeutics, 2006
- Upper gastrointestinal mucosal abnormalities and blood loss complicating low‐dose aspirin and antithrombotic therapyAlimentary Pharmacology & Therapeutics, 2006
- Perforated peptic ulcer: use of pre‐admission oral glucocorticoids and 30‐day mortalityAlimentary Pharmacology & Therapeutics, 2005
- SSRIs and gastrointestinal bleedingBMJ, 2005
- Risk Factors of Mortality in Perforated Peptic UlcerBritish Journal of Surgery, 2000
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Non-steroidal anti-inflammatory drugs and peptic ulcer perforation.Gut, 1985